谷歌浏览器插件
订阅小程序
在清言上使用

A Phase 1 Dose-escalation and Expansion Study of CUE 101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+Head and Neck Cancer Patients

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS(2024)

引用 0|浏览2
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要